Axsome Therapeutics (AXSM) Share-based Compensation (2015 - 2026)

Axsome Therapeutics has reported Share-based Compensation for 12 years, with the latest figure at $23.4 million in Q1 2026.

• Quarterly Share-based Compensation rose 0.56% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.0 million (down 48.73% YoY) and the FY2025 annual result came in at $99.1 million, down 32.4% from the prior year.
• Share-based Compensation improved to $23.4 million in Q1 2026 per AXSM's latest filing, from $6.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $133.8 million in Q2 2025 and troughed at $9197.0 in Q3 2022.
• A 5-year average of $24.7 million and a median of $16.4 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 99.84% in 2022, then jumped 177871.08% in 2023.
• Over 5 years, Share-based Compensation stood at $37.4 million in 2022, then sank by 83.28% to $6.2 million in 2023, then soared by 1209.41% to $81.8 million in 2024, then sank by 92.53% to $6.1 million in 2025, then soared by 283.6% to $23.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $23.4 million, $6.1 million, and $23.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.